Xcout Intel
Disruptive Pharma
Disruptive Pharma develops and commercializes Formulite, a proprietary platform technology designed to enhance the solubility, oral bioavailability, and overall properties of pharmaceutical compounds. The company provides drug development solutions that enable optimized pill sizes and eco-friendly manufacturing for pharmaceutical partners.
Subscribe to see Disruptive Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Disruptive Pharma at a glance
Disruptive Pharma is a health care company headquartered in Sweden. Xcout tracks 4 named people at Disruptive Pharma, including Peter Åsberg (CEO since 2021).
Disruptive Pharma leadership
- Peter ÅsbergCEO since 2021
- Karin BothaCFO since 2026
- Martina FernemanCommercial Director (consultant) since 2025
- Sofia MogensenR&D Director and Project Management (consultant) since 2023
Disruptive Pharma competitors
A few of Disruptive Pharma's closest competitors — see the full list of competitors and alternatives →
Sprint Bioscience is a pharmaceutical company that develops innovative preclinical drug candidates for cancer treatments. Utilizing a fragment-based drug discovery method, the company creates and out-licenses its drug programs to global pharmaceutical partners.
INTREPID Robotics, Inc. provides an AI-driven drug formulation platform designed to accelerate therapeutic development for pharmaceutical and biotechnology companies. The company combines artificial intelligence, automation, and formulation expertise to convert candidate molecules into optimized, manufacturable drug formulations.
Flex Pharma is a specialty pharmaceutical company that develops advanced drug delivery formulations to enhance the bioavailability, tolerability, and dosing flexibility of complex or poorly soluble drugs. The company utilizes its proprietary ElectroNanoSpray (ENS) technology platform to assist pharmaceutical innovators in optimizing drug performance for clinical trials and patient care.
Fulgent Pharma LLC is a clinical-stage pharmaceutical company that develops innovative cancer therapeutics using a patented nanoencapsulation technology. The company focuses on improving existing chemotherapy drugs and creating new drug candidates to treat various cancers while reducing toxicity and enhancing drug delivery and safety.
Day Three Labs Inc. is a biotechnology and pharmaceutical formulation company based in Denver, Colorado, founded in 2021. The company specializes in nanodelivery technologies that enhance the bioavailability of cannabinoid and pharmaceutical compounds.
Biora Therapeutics is a U.S. biotechnology company developing ingestible, device-based platforms for delivering biologic medicines to targeted areas of the gastrointestinal tract and into systemic circulation. Its technologies are intended for use by pharmaceutical and biotechnology companies developing oral or targeted biologic therapies.
Get Disruptive Pharma's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Disruptive Pharma in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access